Status:
TERMINATED
Impact of LDL-cholesterol Lowering on Platelet Activation
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Amgen
Conditions:
Familial Hypercholesterolemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary goal is to assess the impact of Evolocumab therapy on platelet function of familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab is a humanized monocl...
Detailed Description
Hyperlipidemia as exemplified by familial hypercholesterolemia is associated with increased platelet activation and an underlying pro-coagulant state. Hyperlipidemia primes platelets and increases pla...
Eligibility Criteria
Inclusion
- Subjects who have a clinical diagnosis of familial hypercholesterolemia (FH)
- Subjects who are referred to Dr. Ginsberg's Lipid Practice for treatment with PCSK9 inhibitor
- Subjects with LDL cholesterol levels \>100 mg/dl on baseline treatment with statins and/or ezetimibe
Exclusion
- Children under 18 years of age
Key Trial Info
Start Date :
November 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03331666
Start Date
November 16 2018
End Date
February 4 2020
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032